Title of Dataset: Cohesin\_mutations\_in\_acute\_myeloid\_leukemia\_data

========================================================================

Patients with acute myeloid leukemia (AML) from previously reported

multicenter trials: AML96 \[NCT00180115\], AML2003 \[NCT00180102\],

AML60+ \[NCT 00180167\], SORAML \[NCT00893373\] Pre-treatment peripheral

blood or bone marrow aspirates were screened for genetic alterations

using next-generation sequencing (NGS)

Results: We identified distinct co-mutational patters for mutations of

STAG2, which were associated with normal karyotypes (NK) and concomitant

mutations in IDH2, RUNX1, BCOR, ASXL1, and SRSF2. Mutated RAD21 was

associated with NK, mutated EZH2, KRAS, CBL, and NPM1. We found almost

complete mutual exclusivity of genetic alterations of individual cohesin

subunits. Conclusion: This mutual exclusivity may be the basis for

therapeutic strategies via synthetic lethality in cohesin mutated AML.

Data description: Cohesin mutation status is displayed differentiating

between RAD21, STAG2, SMC3, SMC1A p.HGVS codes are used to denote

specific alterations presence (1) or absence (0) of a feature is

reported European Leukemia Net 2022 (ELN2022) risk stratification

(Döhner et al., Blood 2022) was used.

Further information on clinical trial protocols can be obtained from

www.clinicaltrials.gov using the following identifiers: NCT00180115,

NCT00180102, NCT 00180167, SORAML NCT00893373